PMC:7205724 / 0-204
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1 | 30-38 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 132-147 | Body_part | denotes | immunoglobulins | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 30-38 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T1 | 89-113 | Chemical | denotes | immunosuppressive agents | http://purl.obolibrary.org/obo/CHEBI_35705 |
T2 | 153-168 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
LitCovid-sample-MedDRA
Id | Subject | Object | Predicate | Lexical cue | meddra_id |
---|---|---|---|---|---|
T1 | 132-147 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | immunoglobulins | http://purl.bioontology.org/ontology/MEDDRA/10021496 |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 89-106 | http://purl.obolibrary.org/obo/IDO_0000610 | denotes | immunosuppressive |
LitCovid-sample-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T1 | 153-168 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T1 | 30-38 | Species | denotes | COVID-19 | NCBItxid:2697049 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-39 | Sentence | denotes | Towards treatment planning of COVID-19: |
T2 | 40-114 | Sentence | denotes | Rationale and hypothesis for the use of multiple immunosuppressive agents: |
T3 | 115-168 | Sentence | denotes | Anti-antibodies, immunoglobulins, and corticosteroids |
T4 | 170-180 | Sentence | denotes | Highlights |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
1 | 30-38 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sample-Enju
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T0 | 0-7 | IN | denotes | Towards |
T1 | 8-17 | NN | denotes | treatment |
T2 | 18-26 | NN | denotes | planning |
T3 | 27-29 | IN | denotes | of |
T4 | 30-38 | NN | denotes | COVID-19 |
T5 | 38-39 | -COLON- | denotes | : |
T6 | 40-49 | NN | denotes | Rationale |
T7 | 50-53 | CC | denotes | and |
T8 | 54-64 | NN | denotes | hypothesis |
T9 | 65-68 | IN | denotes | for |
T10 | 69-72 | DT | denotes | the |
T11 | 73-76 | NN | denotes | use |
T12 | 77-79 | IN | denotes | of |
T13 | 80-88 | JJ | denotes | multiple |
T14 | 89-106 | JJ | denotes | immunosuppressive |
T15 | 107-113 | NNS | denotes | agents |
T16 | 113-114 | -COLON- | denotes | : |
T17 | 115-130 | NNS | denotes | Anti-antibodies |
T18 | 130-131 | -COMMA- | denotes | , |
T19 | 132-147 | NNS | denotes | immunoglobulins |
T20 | 147-148 | -COMMA- | denotes | , |
T21 | 149-152 | CC | denotes | and |
T22 | 153-168 | NNS | denotes | corticosteroids |
T23 | 170-180 | NNS | denotes | Highlights |
T24 | 181-182 | IN | denotes | • |
T25 | 184-188 | NNP | denotes | IVIG |
T26 | 188-189 | -COMMA- | denotes | , |
T27 | 190-198 | VBN | denotes | combined |
T28 | 199-203 | IN | denotes | with |
R0 | T2 | T0 | arg2Of | planning,Towards |
R1 | T2 | T1 | arg1Of | planning,treatment |
R2 | T2 | T3 | arg1Of | planning,of |
R3 | T4 | T3 | arg2Of | COVID-19,of |
R4 | T2 | T5 | arg1Of | planning,: |
R5 | T6 | T7 | arg1Of | Rationale,and |
R6 | T8 | T7 | arg2Of | hypothesis,and |
R7 | T7 | T9 | arg1Of | and,for |
R8 | T11 | T9 | arg2Of | use,for |
R9 | T11 | T10 | arg1Of | use,the |
R10 | T11 | T12 | arg1Of | use,of |
R11 | T15 | T12 | arg2Of | agents,of |
R12 | T15 | T13 | arg1Of | agents,multiple |
R13 | T15 | T14 | arg1Of | agents,immunosuppressive |
R14 | T7 | T16 | arg1Of | and,: |
R15 | T17 | T18 | arg1Of | Anti-antibodies,"," |
R16 | T19 | T18 | arg2Of | immunoglobulins,"," |
R17 | T21 | T20 | arg1Of | and,"," |
R18 | T18 | T21 | arg1Of | ",",and |
R19 | T22 | T21 | arg2Of | corticosteroids,and |
R20 | T25 | T24 | arg1Of | IVIG,• |
R21 | T25 | T26 | arg1Of | IVIG,"," |
R22 | T25 | T27 | arg2Of | IVIG,combined |
R23 | T27 | T28 | arg1Of | combined,with |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 132-147 | Body_part | denotes | immunoglobulins | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 30-38 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-39 | Sentence | denotes | Towards treatment planning of COVID-19: |
T2 | 40-114 | Sentence | denotes | Rationale and hypothesis for the use of multiple immunosuppressive agents: |
T3 | 115-168 | Sentence | denotes | Anti-antibodies, immunoglobulins, and corticosteroids |
T4 | 170-180 | Sentence | denotes | Highlights |